Baker Bros. Advisors Adds $33M in Aktis Oncology, Inc. ($AKTS)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors acquired a new position in Aktis Oncology, Inc. ($AKTS), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 996,351 shares of Aktis Oncology, Inc.. Baker Bros. Advisors's holdings in Aktis Oncology, Inc. were worth $32.71 million as of its most recent filing.
Aktis Oncology, Inc. Stock Up 27.3%
Shares of Aktis Oncology, Inc. ($AKTS) traded around $32.83 on Sunday, up 27.3% for the day.
Aktis Oncology, Inc. Earnings
Analysts Set New Price Targets
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Get Aktis Oncology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $AKTS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.